A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

NCT03761849 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

899

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntingtons Disease

Interventions

DRUG: RO7234292
DRUG: Placebo

Sponsor

Hoffmann-La Roche